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LC–MS/MS‑based in vitro and in vivo
investigation of blood–brain barrier integrity
by simultaneous quantitation of mannitol
and sucrose
Behnam Noorani1,4, Ekram Ahmed Chowdhury1,4, Faleh Alqahtani2, Yeseul Ahn1,4, Dhavalkumar Patel1,
Abraham Al‑Ahmad1,4, Reza Mehvar3 and Ulrich Bickel1,4*

Abstract
Background: Understanding the pathophysiology of the blood brain–barrier (BBB) plays a critical role in diagnosis
and treatment of disease conditions. Applying a sensitive and specific LC–MS/MS technique for the measurement of
BBB integrity with high precision, we have recently introduced non-radioactive [13C12]sucrose as a superior marker
substance. Comparison of permeability markers with different molecular weight, but otherwise similar physicochemi‑
cal properties, can provide insights into the uptake mechanism at the BBB. Mannitol is a small hydrophilic, uncharged
molecule that is half the size of sucrose. Previously only radioactive [3H]mannitol or [14C]mannitol has been used to
measure BBB integrity.
Methods: We developed a UPLC–MS/MS method for simultaneous analysis of stable isotope-labeled sucrose and
mannitol. The in vivo BBB permeability of [13C6]mannitol and [ 13C12]sucrose was measured in mice, using [ 13C6]sucrose
as a vascular marker to correct for brain intravascular content. Moreover, a Transwell model with induced pluripotent
stem cell-derived brain endothelial cells was used to measure the permeability coefficient of sucrose and mannitol
in vitro both under control and compromised (in the presence of IL-1β) conditions.
Results: We found low permeability values for both mannitol and sucrose in vitro (permeability coefficients of
4.99 ± 0.152 × 10−7 and 3.12 ± 0.176 × 10−7 cm/s, respectively) and in vivo (PS products of 0.267 ± 0.021 and
0.126 ± 0.025 µl g−1 min−1, respectively). Further, the in vitro permeability of both markers substantially increased in
the presence of IL-1β. Corrected brain concentrations (Cbr), obtained by washout vs. vascular marker correction, were
not significantly different for either mannitol (0.071 ± 0.007 and 0.065 ± 0.009 percent injected dose per g) or sucrose
(0.035 ± 0.003 and 0.037 ± 0.005 percent injected dose per g). These data also indicate that Cbr and PS product values
of mannitol were about twice the corresponding values of sucrose.
Conclusions: We established a highly sensitive, specific and reproducible approach to simultaneously measure the
BBB permeability of two classical low molecular weight, hydrophilic markers in a stable isotope labeled format. This
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method is now available as a tool to quantify BBB permeability in vitro and in vivo in different disease models, as well
as for monitoring treatment outcomes.
Keywords: Blood–brain barrier, Mannitol, Sucrose, Vascular space correction, Permeability coefficient, Brain uptake
clearance, In vitro and in vivo correlation

Introduction
The blood–brain barrier (BBB) maintains the homeostatic environment of the CNS by separating circulating
blood from the central nervous system [1]. It encompasses specialized endothelial cells with a basal lamina
that supports the abluminal surface of the endothelium
along with other supporting cells, such as pericytes,
astrocytes, and neurons [1]. The brain microvascular
endothelial cells with tight junctions and transporter
proteins are the primary and main gatekeepers for the
transportation of nutrients and metabolites, and for the
efflux of neurotoxins [2, 3]. The BBB dysfunction and
breakdown contribute to neurological disorders due
to the transfer of harmful blood components into the
brain, irregular transport, and dysregulated clearance of
metabolites associated with reduced cerebral blood flow
[4]. Therefore, measuring the functional integrity of BBB
by various methods such as paracellular markers is frequently performed in in vitro and in vivo studies.
There are many technical and conceptual pitfalls associated with the experimental application of supposedly
paracellular markers and the subsequent interpretation
of data. One important aspect, which deserves mentioning, is the fact that these markers can serve two distinct
purposes. The first purpose is that, due to their characteristically low BBB permeability, these substances are
often used as so-called vascular markers. This is commonly the case when other, more permeable agents are
measured in the same study. When used as a vascular
marker, it is assumed that neglecting the extent of brain
uptake of the substance during a short experimental time
period (1 minute or less) does not significantly compromise the study. Therefore, any concentration measured
in whole brain tissue presumably represents brain intravascular space (with reference to concentration in whole
blood), or brain plasma volume (with reference to plasma
concentration). Such intravascular space values can then
be used to correct brain concentrations of other substances, before calculating their BBB permeability. The
second purpose is to determine the genuine permeability
values of the BBB markers themselves, which is not zero.
The latter measurement, of course, also requires proper
correction for intravascular volume. Major damage to the
BBB, caused by severe disease processes, such as stroke
or a relapse phase of multiple sclerosis, may be readily
detected using various imaging techniques and a range

of markers. However, for the quantification of subtle
BBB impairment, markers with naturally low permeability, such as sucrose or mannitol, are used, because even
a minor degree of barrier damage is expected to have a
noticeable effect on their permeability. Such damage has
been observed in acute situations, for instance caused by
peripheral inflammatory pain [5, 6], and after major surgery, where it has been connected to the occurrence of
postoperative cognitive dysfunction in animal studies [7]
and in patients [8]. Subtle BBB damage has also been postulated to play a role in the pathophysiology of chronic
diseases like Alzheimer’s dementia [9] or small vessel disease [10]. However, there is still uncertainty, as functional
BBB changes related to drug transport could not be confirmed in animal models of Alzheimer’s disease [11, 12].
Radiolabeled versions of sucrose, in particular 
[14C]
sucrose, have long been used as low molecular weight,
hydrophilic markers. We have recently introduced [ 13C12]
sucrose as a superior marker substance, which is nonradioactive and can be quantified by a sensitive and
highly specific LC–MS/MS technique [13, 14]. The disaccharide sucrose may be considered as the most widely
accepted standard for the precise measurement of paracellular BBB permeability due to its properties, such as
being uncharged, absence of protein binding, and metabolic stability in the circulation [15]. Our lab has focused
on understanding the uptake mechanism at the BBB of
different molecular weight markers, which have similar
physicochemical properties. Mannitol is a small molecule
that is about half the size of sucrose and has otherwise
similar characteristics as sucrose as a marker for the BBB.
It also has a molecular weight (182 Da) in the range of
many small-molecule drugs.
Furthermore, mannitol has been widely used over
the last 30 years in the lactulose/mannitol (L/M) test as
a common dual-sugar test to assess the intestinal barrier function [16]. The radiotracer version of mannitol
has been used for measurement of BBB integrity, but it
requires a radioactive license and special handling skills
[17–22]. We have also shown that using the radiolabeled
versions of a marker, in particular [14C]sucrose, might
result in a substantial overestimation of the true BBB permeability due to the presence of low level lipid-soluble
impurities in the radiolabeled versions of the marker.
The first objective of the present study was to develop
a UPLC–MS/MS method, which allows simultaneous
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analysis of stable isotope-labeled sucrose and mannitol.
The second objective was to show the application of these
markers in BBB in an vitro and in vivo model. The application of a stable isotope-labeled version of mannitol as
a marker for BBB has not been reported yet. Different
stable isotope-labeled versions of mannitol and sucrose,
respectively, are commercially available. The variants of
each marker coelute from a BEH-amide UPLC column,
but are separate from each other. This allowed the simultaneous use of both markers for BBB permeability analysis. Furthermore, for the first time, one variant of [13C]
sucrose was used to correct vascular space for mannitol
and sucrose simultaneously. Thus, we selected a suitable combination of mass transitions and settings of the
mass detector to detect and quantify [13C6]mannitol and
[13C12]sucrose as permeability markers, [2H8]mannitol
and [2H2]sucrose as internal standards, and [13C6]sucrose
as a vascular marker. Our method offers novel accurate
biomarkers of different sizes for permeability measurements of the BBB in the preclinical phase.

Methods
Chemicals and reagents

[13C6]mannitol, [2H8]mannitol, [13C12]sucrose, [13C6]
sucrose, and [2H2]sucrose were obtained from Omicron
Biochemicals (South Hill Street, South Bend, IN, USA).
LC–MS grade water was purchased under the brand
name J.T. Baker from Avantor Performance Materials,
Inc. (Center Valley, PA). LC–MS/MS grade acetonitrile,
water, and analytical grade ammonium hydroxide were
purchased from Fisher Scientific (Fair Lawn, NJ, USA).
For anesthesia, isoflurane was purchased from Lloyd
Laboratories (Shenandoah, IA, USA). Heparin solution
was purchased from APP Pharmaceuticals (Schaumburg,
IL, USA). All other chemicals were analytical grade and
obtained from commercial sources.
Analytes were detected using an AB SCIEX QTRAP®
5500 triple quadrupole mass spectrometer (MS) attached
to a Nexera UPLC system (Shimadzu Corporation). The
UPLC system contained an autosampler (Sil-30AC),
pumps (LC-30AD), a controller (CBM-20A), a degasser
(DGA-20A5), and a column oven (CTO-30A). Analyst
software was used for data acquisition and quantification.
Chromatographic separation was performed using an
Acquity B.E.H. amide (2.1 mm × 50 mm, 1.7 μm; Waters,
Milford, MA, USA), attached to an inline filter with a
pore size of 0.2 μm as a pre-column. The isocratic elution
was acetonitrile: water: ammonium hydroxide (73:27:0.1,
v/v), at a flow rate of 0.2 mL/min. The column temperature was maintained at 45 °C, and the autosampler was
at 4 °C. The total run time was 6 min. However, MS data
Mass spectrometric and chromatographic conditions
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were collected from 1 to 4.5 min only, and the valve was
diverted to waste before and after that time. Electrospray
ionization with multiple reactions monitoring system in
negative mode was used for the ionization source. The
mass spectrometer parameters for [13C12]sucrose, [13C6]
sucrose and [2H2]sucrose were optimized in our previous
study [13], however, [13C6] and [2H2]sucrose mass spectrometer parameters were changed due to presence of an
interfering peak in the blank plasma and brain samples at
the same retention time when combined with mannitol
transitions. The mass spectrometer conditions for [13C6]
and [2H8]mannitol were optimized to get optimum M−
H−1 signal by continuous infusion of 100 ng/ml mannitol solution with an infusion pump. The optimized mass
spectrometer parameters were as follows: ion spray voltage, − 4500 V; collision gas, high; curtain gas, 30 psi; temperature, 600 °C; ion source gas 1 (nebulizer gas), 55 psi;
and ion source gas 2 (turbo gas), 55 psi.
For [13C6] and 
[2H8]mannitol, the m/z transitions
187 → 92 and 189 → 73 were selected, respectively. Also,
the transitions 353 → 92, 347 → 179 and 343 → 71 were
used for [13C12], [13C6] and [ 2H2]sucrose.
Standard curve preparation

Stock solutions of triple analytes [ 13C6] mannitol, [13C12],
and [13C6]sucrose were prepared in water at a concentration of 10 mg/mL. Plasma standard curves were made
by adding blank mouse plasma to stock solutions to get
plasma concentrations of 1–100 μg/mL. Then, each concentration was diluted 100-fold in water to obtain specific plasma calibration standards of 10–1000 ng/mL.
For brain standard curve, blank brain tissue was homogenized in water (1:19), and triple analytes were spiked
into the homogenized brain. Homogenate concentrations
ranging from 5 to 400 ng/mL were prepared by serial
dilution.
Sample preparation

For the deproteination process, all samples were diluted
tenfold in acetonitrile: water (80:20) containing 20 ng/
mL of 
[2H2]sucrose and 
[2H8]mannitol. Then, precipitated samples were vortexed and centrifuged at 20,000g
for 10 min. The supernatant was transferred into autosampler inserts, and a sample volume of 5 μL was injected
into the UPLC column.
Method validation
Selectivity

Blank matrix samples from mice containing no analyte
were run to obtain the selectivity of the method. Also, to
ensure that there is no interference between analyte transitions, neat samples of single analytes without matrix
were run.
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Accuracy and precision

Inter and intra-day runs were performed to determine
the accuracy and precision of the method. The quality
control samples (low, medium, and high concentrations) were evaluated against calibration curves. The
accuracy was calculated as a percentage of measured
concentration over nominal concentration. Precision
was calculated as a percentage of relative standard
deviations (RSD). The acceptable inter and intra-run
limits for the accuracy were set at 85–115% for the
middle and high concentrations and 80–120% for the
low concentration. The standard precision values were
15% (medium and high concentrations) or 20% (low
concentration).
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The concentration of the analytes in the neat samples was
compared to the standard curve.
Long‑term stability

Long term storage stability of different isotope of sucrose
was checked in our previous study [13]. In this section,
long term stability of [13C6]mannitol was evaluated for
the diluted plasma samples and brain homogenate at
− 80 °C. Quality control samples at low, medium and
high concentrations of analyte in the brain and plasma
(n = 3) were stored at − 80 °C for 2 months. The stored
samples were then compared against standards in order
to assess stability.
In vivo application of the method

Linearity

The linearity of calibration curves was evaluated by the
coefficient of determination (r2) of the linear regression analysis of the concentration–response data using
a weight of 1/x, where x is the concentration. Weighting by 1/x is superior to analysis with equal weights, on
the strength of higher accuracy and less variability at low
concentrations.
Recovery

The recovery of triple analytes was calculated in diluted
plasma and homogenized brain. We expected similar
recovery of the sucrose analytes as mentioned in the
results described previously [13, 14] since all of the analytes are stable labeled isotopes of the same chemical
entity. Three concentrations representing low, medium,
and high were selected from the calibration curve. In
case of plasma matrix, 10, 100, and 1000 ng/mL were
used, and 5, 50, and 400 ng/mL were selected for the
brain homogenate. Five replicate samples were prepared
in each of the respective matrices, as well as samples with
equivalent concentrations in water as reference. The samples and references were subjected to the sample preparation method described above, and the peak areas of
analytes were determined. Recovery was calculated as
the percent of the ratio of peak areas Sample/Reference,
where sample refers to the matrix and reference to water
(neat sample), respectively.
Freeze–thaw stability

The freeze–thaw stability was performed by subjecting
two neat concentrations of analytes (50 and 500 ng/mL)
to three freeze/thaw cycles (n = 3). Prepared samples
were stored at − 80 °C and thawed at room temperature
for 1 h, in order to replicate the experimental conditions.

Two groups of anesthetized C57BL/6J mice were used
to perform the pharmacokinetic study. 8–10 weeks old
female C57BL/6J mice with 23–27 g bodyweight were
purchased from Jackson Laboratories (Bar Harbor, ME,
USA). The experimental protocols were approved by
the Institutional Animal Care and Use Committee at
Texas Tech University Health Sciences Center and followed current NIH guidelines. A silicone face mask was
used to apply isoflurane (4% for induction, 1.5–2% v/v for
maintenance) in 70% nitrous oxide/30% oxygen at a flow
rate of 1 L/min. By skin incisions, the jugular veins were
exposed bilaterally at the neck for IV injections and blood
sampling, respectively. [13C6]mannitol and [13C12]sucrose
(10 mg/kg) were co-injected as an IV bolus dose into
the jugular vein. Then, at 1, 5, 10, 20, and 30 min after
injection, blood samples (40 µL) were collected from
the contralateral jugular vein. The samples were used to
generate plasma concentration–time curves in each individual animal. Two groups of animals were used to investigate the effect of [13C6]sucrose application as vascular
marker compared to transcardiac perfusion for vascular
space correction (washout group). In the washout group
(n = 6), the thorax was opened immediately after the last
time point of sampling (30 min), and 20 mL phosphate
buffered saline (pH 7.4) at room temperature, was used
to perform the vascular perfusion via the left ventricle of
the heart (flow rate of 2 mL/min) using a Harvard syringe
pump. In order to facilitate the outflow of blood from the
brain and to visually confirm the complete blood removal
from the brain following perfusion, both jugular veins
were cut open at the start of perfusion. In the second
group of the animals (n = 6), a bolus dose of the vascular
marker [13C6]sucrose (10 mg/kg in saline) was injected
intravenously 30 s before the last sampling time point.
Afterwards, the animals were euthanized by decapitation. Collected blood samples were centrifuged, and
supernatant plasma was separated for further analysis.
Meninges were removed from the collected brains, and
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the forebrains were weighted without olfactory bulbs,
cerebellum, or brain stem. Then, the brain and plasma
samples homogenized and diluted respectively according to the sample preparation steps described in UPLCMS/MS section and the homogenized brain and diluted
plasma were stored at − 80 °C until measurement by the
UPLC-MS/MS system.
Analyte
The value of corrected brain concentration (Cbr−corr ) in
13
the vascular marker group, which received [ C6]sucrose,
was determined as follows:
Analyte

Analyte

Cbr−corr =

(Vd − V0 ) × Cpl
1 − V0

(1)

Here, Vd is the apparent volume of distribution of the
BBB permeability marker, 
[13C6]mannitol and 
[13C12]
sucrose, V0 is the apparent volume of distribution of the
analyte
is the termivascular marker, [13C6] sucrose, and Cpl
nal (30 min) plasma concentration of [13C6]mannitol or
[13C12]sucrose. Vd and V0 values were obtained using the
following two equations.
analyte

Vd = Cbr

analyte

/Cpl

vascular marker
vascular marker
V0 = Cbr
/Cpl

(2)

(3)

analyte

where Cbr
is the total uncorrected brain concentration of 
[13C6] mannitol or 
[13C12]sucrose and
vascular marker
Cbr
is the total (uncorrected) brain concentrations of [13C6]sucrose, at the terminal sampling time
vascular marker
(30 min), and Cpl
is the terminal plasma concentration of the vascular marker at 30 min.
Brain tissue concentration values in the washout group,
which had undergone buffer washout, were considered
as corrected for intravascular content. Values for brain
uptake clearance, K
 in, also known as the permeabilitysurface area product, were calculated using the following
analyte
equations based on either uncorrected (Cbr
) or coranalyte
rected (Cbr−corr ) brain concentrations of mannitol and
sucrose:
analyte

Kin = Cbr

/AUC0T

analyte

Kin−corr = Cbr−corr /AUC0T

(4)

(5)

where AUCT0 denotes the area under the plasma concentration–time curve from time point 0 to the terminal
sampling time (30 min) for [13C6]mannitol and [13C12]
sucrose. AUCT0 was estimated via the linear-logarithmic
trapezoidal method.

For a comparison between in vitro and in vivo models, the Kin values or permeability surface area products
(PS) were converted to permeability coefficients, taking
120 cm2/g of brain as the surface area of the BBB in vivo
[23].
In vitro application of the method
iPSCs differentiation to BMECs

IMR90-c4 induced pluripotent stem cell line was used
from the WiCell cell repository (WiCell, Madison, WI,
USA). iPSCs were differentiated into brain microvascular
endothelial cells (BMECs) following the established protocol [24, 25]. Undifferentiated stem cells were seeded on
six well tissue culture treated plates coated with matrigel
(C-Matrigel; Corning, Corning, MA, USA) in Essential 8
medium (E8 Thermo Fisher, Waltham, MA, USA) containing 10 μM Y-27632 (Tocris, Minneapolis, MN, USA)
at a density of 100,000 cells/mL. Cells were maintained in
E8 for 3 days prior to differentiation. Then, differentiation
was initiated using unconditioned medium [UM: Dulbecco’s modified Eagle’s medium/F12 with 15 mM HEPES
(Thermo Fisher, Waltham, MA, USA), 20% knockout
serum replacement (Thermo Fisher, Waltham, MA,
USA), 1% non-essential amino acids (Thermo Fisher,
Waltham, MA, USA), 0.5% Glutamax (Thermo Fisher,
Waltham, MA, USA) and 0.1 mM β-mercaptoethanol
(Sigma-Aldrich, St. Louis, MO, USA)] and maintained
for 6 days. After 6 days, cells were incubated for two
days with EC++ media [human serum-free endothelial medium (hESFM, Thermo Fisher, Waltham, MA,
USA) supplemented with 1% bovine platelet-poor
plasma-derived serum (PDS, Alfa Aesar, Ward Mill, MA,
USA), 10 ng/mL bFGF and 10 μM retinoic acid (SigmaAldrich)]. Upon eight days of differentiation, cells were
removed by accutase (Corning) treatment and seeded as
single cells on 24-well Transwells (polyester, 0.4 μm pore
size; filter area 0.33 cm2, Corning) coated with a solution of collagen from human placenta (Sigma-Aldrich)
and bovine plasma fibronectin (Sigma-Aldrich) (400 μg/
mL collagen IV and 100 μg/mL fibronectin) at a density
of 1,000,000 cells/cm2. Twenty-four h after seeding, EC–
medium was added (EC medium supplemented with 1%
platelet-poor derived serum). Purified endothelial monolayers were formed on day 10 of the experiment, and
permeability barrier function tests were performed 48 h
after seeding on the Transwell system.
Measurement of barrier function

Barrier integrity of BMECs monolayer was obtained
by measuring transendothelial electrical resistance
(TEER) while using a Millicell ERS electrode (Millipore,
Bedford, MA, USA). After conducting three measurements for each insert (n = 3), the average resistance
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was obtained. Paracellular permeability was assessed by
adding 1 mg/mL of [13C6] mannitol and [13C12] sucrose
to the donor site of the Transwell system. Then, 50 μL
of aliquots were collected from the acceptor (basolateral chamber) at 10, 20, 30, 60, and 120 min. At the
end of the experiment, the donor and acceptor samples
were diluted in water to be in the range of standard
curve (10–1000 ng/mL) and the aforementioned preparation steps were performed to measure the concentrations with UPLC–MS/MS system.
The clearance or permeability-surface area product
(PS) for mannitol and sucrose were calculated using the
following steps: First, the cleared volume up to each time
point was calculated from the following equation. Then,
linear regression applied to the plotted cleared volume
versus time for samples and blank to obtain the PS of the
Transwell system.

Measurement of partition coefficients of Mannitol
and Sucrose

By using an established method, the partition coefficients of [13C6]mannitol and [13C12]sucrose between
1-octanol and water were determined [15]. For this
purpose, an equal volume of 1-octanol and water were
mixed together at room temperature overnight with
continuous stirring. Then 100 μg/mL of [13C6]mannitol
and [13C12]Sucrose were added to 5 mL saturated water,
and then the mixture was added to 5 mL of saturated
1-octanol in a glass scintillation vial. Subsequently,
the glass vial was placed in a rotary machine, and the
content was mixed for 30 min. 500 μL samples were
taken from both the water and 1-octanol phase for further analysis with LC-MS/MS. The water samples are
diluted 100-fold, and the 1-octanol samples remain
undiluted for this purpose.

Cleared Volume = (C(acceptor) ∗ V (acceptor))/C(donor)

(6)
Here, Cacceptor referred to measured concentration in
acceptor compartment at a given sampling time point,
and Vacceptor referred to the volume of acceptor compartment. Also, C donor is the concentration in donor compartment. Afterwards, the permeability coefficient (P)
was obtained by the following equations:
P = PS/S

(7)

1
1
1
=
−
PCells
Ptotal
Pblank

(8)

The permeability coefficient (P) was obtained by dividing the PS to insert surface area (S) (cm2) Eq. (7), and
then the permeability coefficient of the cell monolayer
(Pcells) was obtained by subtracting the permeability coefficient of Transwell (Ptotal) from the permeability coefficient of the coated filter (Pblank) Eq. (8).
Measurement of permeability coefficient of Mannitol
and Sucrose in presence of inflammatory cytokine

The effect of Interleukin 1 beta (IL-1β) on the permeability of mannitol and sucrose in in vitro model of BBB
(iPSC-derived BMECs) was also measured. To mimic
inflammatory conditions, the Transwell model was
exposed to media supplemented with 10 and 100 ng/mL
IL-1β (Peprotech, Cranbury, NJ) for 24 h (n = 3). Then,
the medium was removed, and fresh medium containing 1 mg/mL of sucrose and mannitol was added to the
apical side of the Transwell. The permeability coefficients
of markers were measured as previously described. Also,
the TEER values of iPSC-derived BMECs were measured
before and after exposure to IL-1β.

Statistical analysis

Statistical analysis of data was performed using Prism 8
(GraphPad Software, La Jolla, CA). All experimental metrics were collected across at least three biological replicates. The student’s paired t-test was used for comparison
of uncorrected and corrected vascular space for the same
mice. Unpaired two tailed t-test was used for comparison of two groups. Data with 3 groups were analyzed by
1-way ANOVA, followed by Tukey’s multiple comparison test. In all cases, a p value < 0.05 was considered significant. Data are presented as mean ± SD or individual
values.

Results
Method development and validation

The mass spectra of [13C12], [13C6], and [2H2]sucrose have
been reported in our previous study [13]. The best m/z
transition of stable isotopes of mannitol was selected
based on signal to noise ratio and higher sensitivity, see
Fig. S1 in Additional file 1.
Selectivity

Figure 1 depicts the chromatograms of single analyte
neat samples of mannitol and sucrose prepared in water
with no cross channel interference between transitions
observed. We also showed the lowest calibration standard, blank matrix and internal standard in plasma and
brain matrix (Fig. 2). We found no interference in matrix
samples. However, [13C6]sucrose (347 > 179) had a peak
at retention time approx. 1.7 and 2.6 min in plasma and
brain matrix, respectively. Also, [2H2]sucrose transition (343 > 71) displayed the same peaks at the retention
time of 1.7 and 2.7 min for plasma and brain matrix,
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Fig. 1 Chromatograms of single analyte neat samples of [13C6]mannitol, [13C12]sucrose, [13C6] sucrose, [2H8]mannitol, and [ 2H2]sucrose, prepared in
LC–MS/MS grade water, with all considered transitions

respectively. These peaks do not interfere with sucrose
peak at the retention time of 2.2 min.
Accuracy and precision

The data for Inter- and Intra-run accuracy and precision
in plasma and brain samples are included in Additional
file 1: Table S1 and S2. Both plasma and brain values were
within the limits of Food and Drug Administration (FDA)
guidelines for the method validation. Moreover, the calibration curves generated in the ranges of 10–1000 ng/mL
and 5–400 ng/mL for plasma and brain, were found to be
linear with r 2 > 0.99 across all Intra and Inter-assay runs.

Recovery and stability

Recoveries of [13C6]mannitol, [13C12]sucrose and [13C6]
sucrose as the analytes of the method were performed for
plasma and brain matrix at low, medium, and high concentrations. Based on Table S3, the recoveries of analytes
were relatively high (≥ 95%) in all the tested matrices.
Plus, the recovery of both sucrose analytes was similar to
our previously developed method [13, 14]. In addition to
high recovery, these data suggest minimal or no matrix
effect on the analyte signal intensity.
The freeze–thaw stability of [13C6]mannitol was determined for 50 and 500 ng/ml in water (Additional file 1:
Fig. S2). The results confirmed that mannitol stays stable
at three cycles of freeze–thaw that was similar to sucrose
analytes in our previous study [13]. Results from the long
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Fig. 2 Chromatograms of blank matrices, Lowest calibration standard and internal standard in plasma (a) and brain matrix (b)

term storage stability also showed mannitol was stable
in plasma and brain matrix over the long term. Regarding accuracy, the values of [13C6]mannitol in plasma at
nominal concentrations of 10, 100, and 1000 ng/mL were
96.1%, 109%, and 97.6%, respectively. In case of brain
matrix, the accuracy values for 5, 50 and 400 ng/mL
nominal concentrations were 105%, 97.2%, and 97.5%,
respectively.
In vivo application of the method

A comparative pharmacokinetic study was done in two
groups of anesthetized C57BL/6J mice to show the application of the method. The results of the pharmacokinetic
study are shown in Figs. 3 and 4. The plasma profiles of
both groups (vascular marker group and washout group)
were similar for both mannitol and sucrose, and the areas
under the curve from 0 to 30 min were not significantly
different. Moreover, the plasma profile of mannitol was
similar to sucrose, which showed a biexponential decline
(Fig. 3).

Comparison of the corrected brain concentrations
(washout vs. vascular marker correction) showed no
significant difference for both mannitol and sucrose
(unpaired, two-tailed t-test) (Fig. 4). Cbr (%ID/mL) of
mannitol was 0.071 ± 0.007 and 0.065 ± 0.009 for vascular marker and washout respectively, whereas the
Cbr of sucrose was almost half of mannitol C
 br values
(0.035 ± 0.003 and 0.037 ± 0.005 for vascular marker and
washout respectively). Similarly, comparison of the brain
uptake clearance ( Kin) between these two groups of each
marker showed no significant difference (unpaired, twotailed t-test) (Fig. 4). For example, The K
 in value of mannitol was 0.267 ± 0.021 μL/min g−1 and 0.245 ± 0.013 μL/
min g−1 for the vascular marker and washout groups,
respectively. In terms of comparison of two markers, the 
Kin of mannitol (0.267 ± 0.021 µl g−1 min−1)
was more than two times higher than that of sucrose
(0.126 ± 0.025 µl g−1 min−1).
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Fig. 3 Pharmacokinetic profiles for [13C6]mannitol and [ 13C12]sucrose in mouse plasma up to 30 min after IV bolus (mean ± SD, n = 6)

In vitro application of the method (in vitro‑in vivo
correlation)

Transwell system is widely used in in vitro models of
BBB for drug development and screening [26]. We evaluated the permeability of our novel markers in iPSC
derived brain endothelial cells cultured on the Transwell
membranes. The barrier function of the monolayer was
confirmed by measuring the TEER. The average TEER
value was 1812 ± 54 Ω cm2, which is similar to values
reported in the literature [24, 27]. For a comparison
between in vitro and in vivo models, the K
 in values or
permeability surface area products (PS) were converted
to permeability coefficients, taking 0.33 cm2/well as the
surface area of the Transwell membranes, and 120 cm2/g
of brain as the surface area of the BBB in vivo [23]. The
in vitro permeability coefficient of mannitol and sucrose
was 4.99 ± 0.152 × 10−7 and 3.12 ± 0.176 × 10−7, respectively. Figure 5a depicts the permeability values of the
two markers, with mannitol showing higher permeability compared to sucrose (p < 0.0001 unpaired, two-tailed
t-test). The PS value of mannitol and sucrose in vivo was
0.267 ± 0.021 and 0.126 ± 0.025 µl g−1 min−1 respectively,
which corresponds to a permeability coefficient value
of 3.71 ± 0.296 × 10−8 and 1.75 ± 0.355 × 10−8 cm/s for

mannitol and sucrose, respectively. Figure 5c showed the
in vitro and in vivo correlation of the markers. Interestingly, the P values for mannitol and sucrose in vitro were
only about 13-fold and 18-fold higher than the permeability coefficient in vivo.
The effect of an inflammatory cytokine on the permeability of BBB in the vitro model was examined. As shown
in Fig. 6, the permeability coefficient of mannitol and
sucrose significantly increased from 6.90 ± 0.689 × 10−7
and 4.74 ± 0.314 × 10−7 to 1.67 ± 0.188 × 10−6 and
1.23 ± 0.163 × 10−6, respectively, with 100 ng/mL IL-1β.
Moreover, The TEER values of iPSC-derived BMECs
decreased 38% after 1 day exposure to 100 ng/mL IL-1β.
However, the decrease in the TEER values and increases
in the permeability coefficients of sucrose and mannitol
in the presence of 10 ng/mL IL-1β were not statistically
significant (Fig. 6).
The correlations between log P (partition coefficient)
and in vitro and in vivo permeability coefficients are
shown in Fig. 7. We found that mannitol and sucrose
have a log P of − 2.98 ± 0.033 and − 3.62 ± 0.056. The
permeability coefficient of sucrose is lower compared to
mannitol, reflecting the lower log P value.
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Fig. 4 a, c Differences in brain concentration and brain uptake clearance (Kin) of [ 13C6]mannitol with or without correction by vascular marker. b, d
Cbr and Kin of [13C12]sucrose with or without correction by vascular marker. ***p < 0.001 (n = 6), analyzed by Student’s paired t-test (two-tailed). N.S.
Student’s unpaired t-test

Discussion
The results of our study showed we could accurately
quantify the stable labeled isotopes of mannitol and
sucrose simultaneously in brain and plasma by LCMS/
MS. Our method not only could replace radioactive
tracers of mannitol and sucrose for permeability studies, but also it could detect two different molecular
weight markers by one single run. The radioactive version of mannitol has been used widely in the measurement of the BBB [17–20, 27]. Moreover, mannitol is
also used as a marker in the lactulose/mannitol (L/M)
ratio test as a widespread dual-sugar test to assess the
intestinal barrier function [16]. [13C]mannitol has been
recently presented as a novel biomarker for quantifying
the intestinal permeability [28, 29] but, the validation

of [13C]mannitol as a marker for the BBB has not been
reported. Hence, the mass spectrometry condition of
[13C6]mannitol was optimized by continuous injection
of mannitol solution with injection pump to get the
optimum M–H−1. According to our findings, the most
robust m/z value for 
[13C6]mannitol was 187 → 92,
based on signal to noise ratio.
The dual analytes with a vascular marker of sucrose
were previously developed by our group. In our study,
three analytes (one mannitol and two sucrose) plus two
stable isotope internal standards were easily detected due
to co-elution from a suitable stationary phase and variation of detector signal based on their molecular weight
for each analyte. Figure 2 shows the simultaneous detectability of mannitol and sucrose in the various matrices.
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Fig. 5 a Permeability coefficient (P) of mannitol and sucrose in the Transwell model with TEER value of 1812 ± 54 Ω cm2 (n = 3). b Permeability
coefficient (P) of mannitol and sucrose in the vivo model (n = 6). ****p < 0.0001, analyzed by Student’s unpaired t-test (two-tailed). c In vitro and
in vivo correlation of mannitol and sucrose based on the permeability coefficients

Co-administration of mannitol and sucrose could provide information on the uptake mechanism at the BBB
of markers that have similar physicochemical properties
over a range of molecular weights which covers the vast
majority of marketed drugs [30]. The method has this
feature to be run for single analyte by removing the transition of another anlayte from the method.
To indicate the application of our method in in vitro
studies, we used the Transwell system as the in vitro platform most commonly used for BBB permeability studies. iPSC-derived BMECs were used, which provide high
TEER values resulting in low paracellular permeability.
The iPSC-derived BMECs is considered the ideal cell line
for drug screening and permeability studies [31]. Various BBB permeability markers are currently being used
for Transwell models and advanced microfluidic models,
including sodium fluorescein, radiolabeled sucrose, and

different molecular weight dextrans [32]. Our method
can quantify with high sensitivity and accuracy the integrity of the BBB, when compared to radiolabeled versions
of sucrose or mannitol, and the fluorescent dye sodium
fluorescein, which all have drawbacks.
In terms of comparison between studies using radioactive versions of mannitol and sucrose measured by liquid
scintillation counting with their stable isotopes analyzed
by LC–MS/MS, we have previously shown that [14C]
sucrose had a 6 to sevenfold higher Kin value in vivo than
[13C12]sucrose [15]. We also found by chromatographic
fractionation of [14C]sucrose after in vivo administration that the majority of the brain content of measured
14
C radioactivity belonged to compounds other than the
intact [14C]sucrose [15]. Here, we found the Kin of mannitol (0.267 ± 0.021) 3–7 fold lower than published values
obtained with radioactive versions of mannitol ( [14C] and
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Fig. 6 Permeability coefficient of a mannitol, b sucrose in iPSC-BMECs following treatment with different concentrations of IL-1β. c The effect of
IL-1β cytokine on TEER of iPSC-BMECs. **p < 0.01 and ***p < 0.001, 1-way ANOVA, followed by Tukey’s multiple comparisons test (n = 3)

Fig. 7 a Correlation of in vitro permeability coefficient (n = 3) and log P (n = 5). b Correlation of in vivo permeability coefficient (n = 6) and log P
(n = 5)
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[ 3H] mannitol) [18, 19, 33, 34]. Moreover, Preston and
Haas reported 30–40% lower permeability area products
of chromatographically purified [3H]mannitol compared
to stock solution of the same tracer lot [33, 35]. Comparing the permeability values in different in vitro studies
is challenging due to major differences in experimental design in the published studies, including different
sources of the endothelial cells and different culture conditions, which also results in a range of different TEER
values. Recent iPSC-derived BMECs in vitro models
reported similar permeability values (in the range of 1
 0−6
−7
to 10 cm/s) for mannitol and sucrose as our values [24,
36].
With respect to the small molecule fluorescent dye
marker, sodium fluorescein, we have shown in previous
work that, in order to avoid erroneous interpretation of
brain uptake data, it is mandatory to perform a chromatographic analysis of the unmetabolized (non-glucuronidated) substance, and to measure the free fraction in
plasma [37, 38]. Both is often neglected in publications
using fluorescein in studies on BBB permeability. In addition, the potential role of efflux transporters for fluorescein at the BBB has not been conclusively ruled out
[39–41].
Recent advanced microfluidic BBB models (BBB-ona-chip) have reported general barrier restrictiveness by
measuring paracellular flux with different molecular
weights of dextran (ranging from 3 to 70 kDa). Reporting barrier function for large molecular weight markers
may not accurately predict the integrity of BBB models for small, drug like molecules [42, 43]. Furthermore,
permeability quantifications with such markers are not
reliable in in vivo experiments and result in inaccurate
comparison between these advanced in vitro models and
in vivo models. We obtained a permeability coefficient of
4.99 ± 0.152 × 10−7 and 3.12 ± 0.176 × 10−7 for mannitol
and sucrose, respectively. The permeability was found to
be very low and showed the human in vitro model has
very tight barrier properties. Moreover, the precision
and accuracy of the method supports its use for in vitroin vivo correlation studies with respect to permeability
properties under healthy and disease conditions.
We also found that 100 ng/mL IL-1β resulted in a
change of barrier function in the in vitro model. This
observation is similar to the previous in vitro reports
[44–46]. Additionally, there was a trend towards a
decrease in the TEER value accompanied by an increase
in the permeability coefficients for both markers at
the 10 ng/mL concentration of IL-1β. However, these
changes did not reach statistical significance (Fig. 6),
most likely due to the small sample size used in our study
(n = 3). The developed LC–MS/MS method was successfully applied to measurements of plasma, and brain
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concentrations of mannitol and sucrose after injection
of the markers to mice at a dose of 10 mg/kg. We previously showed that correcting vascular space using [13C6]
sucrose was equally effective as buffer perfusion for
determination of the BBB permeability of [13C12]sucrose
[13]. Interestingly, similar results were obtained when
we used [13C6]sucrose for correcting the vascular space
of mannitol analyte in the brain (Fig. 4). The corrected
Kin and Cbr of analytes showed no significant difference
between the vascular marker and washout groups for
both mannitol and sucrose. However, the uncorrected Kin
and concentration of brain indicated an overestimation,
almost two times higher than the correct values, which
demonstrates the impact of the intravascular content. In
this context it is also apparent that correction of intravascular volume needs to be performed in each individual
animal, rather than by a value determined in a separate
experimental series.
The correction method by vascular marker administration could be practically more advantageous compared
to the washout method in several aspects: Technically, it
is easier to perform, and brain tissue collection is attainable within seconds after the terminal blood sampling,
as opposed to delays for several minutes by performing
thoracotomy and perfusion (e.g., over 10 min in the present study). Furthermore, rapid sampling gains importance when, apart from measuring the BBB permeability,
parts of the brain samples were needed for measurement
of other analytes such as neurotransmitters or metabolites, that may undergo rapid degradation.
By comparing the PK profile of the two markers, we
found that the plasma profiles of mannitol and sucrose
were similar. However, the brain concentrations and Kin
of mannitol were almost two-fold higher than those for
sucrose, which could be related to its lower molecular
weight and higher paracellular diffusibility. An alternative
explanation is the slightly higher lipid solubility of mannitol, with a log P of − 2.98 ± 0.033, which is half a log
order higher than that of sucrose − 3.62 ± 0.055.

Conclusion
In conclusion, the newly developed method allows the
measurement of triple analytes of mannitol and sucrose
in the same sample in a single run. This technique simplifies correction for intravascular plasma space in brain
uptake experiments with sucrose or mannitol and makes
a vascular washout step dispensable. In addition, nonradiolabeled [13C6]mannitol was introduced as BBB
marker for the first time in this study. Last but not least,
this method can now be considered as a very useful tool
in quantifying BBB permeability in different in vitro and
in vivo disease models as well as for monitoring treatment outcomes.
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